ClinicalTrials.gg
Not yet recruitingNCT07941544Updated Nov 17, 2026

Njinsky Ambispective Cellular Product Safety and Outcomes Registry

An observational study in Retinitis Pigmentosa (RP), Autism Disorder and Diminished Ovarian Reserve, sponsored by Njinsky Medical Centre. Not yet recruiting at 1 site in Pakistan. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by Njinsky Medical Centre · Observational

Updated Nov 17, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Other
Enrollment
1,200
Sex
All
01

Study summary

This ambispective observational registry will describe safety events, treatment patterns, and disease-specific clinical assessments among patients receiving cultured umbilical cord mesenchymal stromal cells (UCMSCs), autologous uncultured stromal vascular fraction (SVF), or both as part of routine care at Njinsky Medical Centre. The registry includes separate cohorts for retinitis pigmentosa, autism spectrum disorder, female infertility conditions, and azoospermia. The retrospective component will use eligible routine-care records from 1 January 2020 through 30 November 2026. Prospective enrollment is planned from 1 December 2026 through 31 December 2030, with follow-up at 1, 3, 6, 12 and 24 months after the last treatment session. Patients may be followed by phone or in person. The study will not assign treatment or require additional tests; it will record measures obtained in routine care and information reported or documented at follow-up. Results will be described separately by condition and actual product exposure. The registry is not designed by itself to establish that a product caused a clinical outcome.

Read the detailed description

Design and setting. Single-centre, ambispective observational cohort/patient registry at Njinsky Medical Centre, Lahore. The retrospective component covers routine-care records from 1 January 2020 through 30 November 2026. The prospective component is planned to begin 1 December 2026 and enroll through 31 December 2030. Follow-up is planned at 1, 3, 6, 12 and 24 months after the participant's last administration. Because the last prospective administrations may occur at the end of 2030, final 24-month follow-up and study completion are estimated by 31 December 2032.

Routine-care status. Clinicians and patients make treatment decisions in usual care; the research protocol does not assign a product, dose, route, or schedule. Patients are included if they have a qualifying indication, receive eligible routine-care administration, and permit inclusion under the consent/authorization and ethics process. Existing approvals and consents are reported by the sponsor as covering both retrospective review and prospective follow-up; enter the exact committee reference and dates before PRS release.

Population and cohorts. Four disease-specific cohorts will be described separately: retinitis pigmentosa; autism spectrum disorder (including minors); female infertility conditions, primarily diminished/low ovarian reserve, secondary infertility and amenorrhea; and azoospermia. Clinical diagnoses and eligibility are determined in routine care. Record relevant subtypes and diagnostic details when available. Participants may have multiple indications; count each unique person once in total enrollment and define a primary/index indication for cohort-level summaries, while retaining secondary indication data where applicable.

Exposure. Participants may receive cultured UCMSCs, autologous uncultured SVF, or both. Exposure is recorded session-by-session, including product, date, route, dose/source amount, sequence, and whether products were given at the same or different sessions. Patients may decline liposuction; treatment selection is not randomized. The two products are not assumed equivalent. Disease-specific outcomes and safety will be reported by indication and actual exposure history where data allow.

Data collection. No tests or visits are required solely for the registry. The team will abstract existing clinical information and record outcomes available from routine care. Follow-up may be by telephone or in-person visit. Staff monitor participants for up to 10 hours after each administration and ask specifically about adverse effects at follow-up. Tests, scales and assessments vary by diagnosis and are recorded only when performed as part of care.

Analysis. Analyses will be descriptive and stratified by disease cohort and exposure pattern. Report denominators, available follow-up, missingness and number of sessions. Because treatment is not randomized and selection may reflect clinician judgement, disease severity, availability or patient preference, comparisons and before/after changes will not be interpreted as proof of causal efficacy.

02

Conditions studied

  • Retinitis Pigmentosa (RP)
  • Autism Disorder
  • Diminished Ovarian Reserve
  • Azoospermia
  • Amenorrhea Secondary
  • Azoospermia, Nonobstructive

Keywords

  • Umbilical Cord Mesenchymal Stem Cells
  • SVF
  • UCMSCs
  • Cell-based Interventions
  • Ambispective Cohort
  • Real-World Safety
  • Retinitis Pigmentosa
  • Autism
  • Autism Spectrum Disorder
  • Diminished Ovarian Reserve
  • Low Ovarian Reserve
  • Amenorrhea
  • Azoospermia
  • Stromal Vascular Fraction
03

In context

Retinitis Pigmentosa

278 studies on the registry are indexed under Retinitis Pigmentosa; 72 are open to participants now.

This study's planned enrollment of 1,200 is above the median of 52 across 87 observational studies indexed under Retinitis Pigmentosa.

Browse Retinitis Pigmentosa studies →

Lead sponsor

This is the only study on the registry with Njinsky Medical Centre as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients receiving routine care at Njinsky Medical Centre in Lahore who have a documented diagnosis of retinitis pigmentosa, autism spectrum disorder, a female fertility condition (primarily diminished or low ovarian reserve, secondary infertility, or amenorrhea), or azoospermia, and who receive cultured UCMSCs and/or autologous uncultured SVF. The registry includes eligible participants whose records fall within the retrospective period from January 1, 2020 through November 30, 2026, and eligible participants enrolled prospectively from December 1, 2026 through December 31, 2030. Children with autism spectrum disorder may be included with guardian permission and assent as required by the approved process. The registry does not assign treatment or require additional tests.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The clinical record documents a diagnosis in at least one registry cohort: retinitis pigmentosa, autism spectrum disorder, a female fertility condition, or azoospermia.
  • The participant received at least one routine-care administration of cultured umbilical cord mesenchymal stromal cells, autologous uncultured stromal vascular fraction, or both at Njinsky Medical Centre during the registry period.
  • Retrospective records are included only when use of the data is covered by consent or other authorization approved by the Institutional Review Board.
  • Prospective participants agree to registry inclusion under the approved consent process.
  • For minors, guardian permission and age-appropriate assent are obtained as required by the approved process.

Exclusion criteria

Exclusion Criteria:

  • No qualifying diagnosis is documented.
  • No eligible routine-care administration can be verified.
  • There is no valid consent or other Institutional Review Board-approved basis to use the participant's data.
05

Study design

Observational model
Cohort
Time perspective
Other
Enrollment
1,200 participants (estimated)
Target follow-up
5 Months
Patient registry
Yes

Groups and cohorts

  • Retinitis Pigmentosa

    Patients diagnosed with retinitis pigmentosa in routine care who receive an eligible UCMSC and/or SVF administration at Njinsky Medical Centre.

    Biological: Umbilical Cord Mesenchymal Stem Cells · Biological: Stromal Vascular fraction

  • Autism Spectrum Disorder

    Patients diagnosed with autism spectrum disorder in routine care who receive an eligible administration. Children may be included; use guardian permission and age-appropriate assent as required by the IRB-approved process.

    Biological: Umbilical Cord Mesenchymal Stem Cells

  • Female infertility conditions

    Patients receiving routine care for female fertility conditions, primarily diminished/low ovarian reserve, secondary infertility and amenorrhea, who receive an eligible administration. Record the specific diagnosis per patient.

    Biological: Umbilical Cord Mesenchymal Stem Cells · Biological: Stromal Vascular fraction

  • Azoospermia

    Patients diagnosed with azoospermia in routine care who receive an eligible administration. Record obstructive/non-obstructive classification when available.

    Biological: Umbilical Cord Mesenchymal Stem Cells · Biological: Stromal Vascular fraction

Interventions

  • BiologicalUmbilical Cord Mesenchymal Stem Cells

    Routine-care exposure observed by the registry. The study does not assign treatment. Cultured umbilical cord mesenchymal stromal cells are administered at 1 million cells/kg total. Half is given intravenously and half by the indication-specific route: sub-Tenon for retinitis pigmentosa, intrathecal for autism spectrum disorder, intraovarian for female infertility, or intratesticular for azoospermia. The treating clinician selects the route and schedule. Actual dose, route, dates, and sessions are recorded.

    Also known as: UCMSCs, WJMSCs

  • BiologicalStromal Vascular fraction

    Routine-care exposure observed by the registry. The study does not assign treatment. Autologous uncultured stromal vascular fraction is prepared from approximately 100 to 120 mL of adipose tissue. The resulting pellet is resuspended in saline. Half is administered intravenously and half by the indication-specific route: sub-Tenon for retinitis pigmentosa, intrathecal for autism spectrum disorder, intraovarian for female infertility, or intratesticular for azoospermia. The treating clinician selects the route and schedule. Actual preparation, route, dates, and sessions are recorded.

    Also known as: SVF

06

What researchers measure

Primary outcomes

  1. Participants with one or more adverse effects reported or documented after administration

    Number and proportion of participants with at least one adverse effect recorded during post-administration observation or follow-up. Staff monitor participants for up to 10 hours after each administration and ask participants or caregivers about adverse effects at follow-up. Event type and clinical course are recorded when available. The registry describes events after administration and does not assume causality.

    Time frame: During observation for up to 10 hours after each administration, and at follow-up 1, 3, 6, 12, and 24 months after the participant's last session.

Secondary outcomes

  1. Routine visual acuity assessments

    Visual acuity values recorded in routine care. Record the test result and eye assessed. The registry does not require additional visual acuity testing.

    Time frame: At baseline and at routine-care follow-up 1, 3, and 6 months after the participant's last session, when the measure is obtained.

  2. Routine fundus examination findings

    Findings from fundus examinations documented in routine care. The registry does not require additional examinations.

    Time frame: At baseline and at routine-care follow-up 1, 3, 6, 12, and 24 months after the participant's last session, when the measure is obtained.

  3. Routine optical coherence tomography findings

    OCT results documented in routine care. Record available findings or measurements; the registry does not require additional imaging.

    Time frame: At baseline and at routine-care follow-up 6 months after the participant's last session, when the measure is obtained.

  4. National Eye Institute Visual Function Questionnaire-25 (NEI VFQ-25)

    Measure: National Eye Institute Visual Function Questionnaire-25 (NEI VFQ-25) Composite Score Description: Contains a total of 25 questions and measures patient-reported vision-related functioning and quality of life. The composite score ranges from 0 to 100, with higher scores indicating better vision-related functioning.

    Time frame: At baseline and at routine-care follow-up 1, 3, 6, 12, and 24 months after the participant's last session, when the measure is obtained.

  5. Autism Treatment Evaluation Checklist score ATEC

    Measure: The Autism Treatment Evaluation Checklist (ATEC), Total Score Description: Measures reported autism-related symptoms across communication, sociability, sensory and cognitive awareness, and health and behavior domains. The total score ranges from 0 to 179. Higher scores indicate greater reported symptom burden; lower scores indicate fewer reported symptoms.

    Time frame: At baseline and at routine-care follow-up 1, 3, 6, 12, and 24 months after the participant's last session, when the measure is obtained.

  6. Childhood Autism Rating Scale score (CARS)

    Measure: The Childhood Autism Rating Scale (CARS), Total Score Description: Measures autism-related behaviors and symptom severity. The total raw score ranges from 15 to 60, with higher scores indicating greater symptom severity.

    Time frame: At baseline and at routine-care follow-up 1, 3, 6, 12, and 24 months after the participant's last session, when the measure is obtained.

  7. Social Responsiveness Scale score, Second Edition (SRS-2)

    Measure: Social Responsiveness Scale, Second Edition (SRS-2) Total Score Description: Measures social responsiveness and autism-related social impairment. The total raw score ranges from 0 to 195, with higher scores indicating greater social impairment.

    Time frame: At baseline and at routine-care follow-up 1, 3, 6, 12, and 24 months after the participant's last session, when the measure is obtained.

  8. Vineland Adaptive Behavior Scales, Third Edition (Vineland-3)

    Measure: Vineland Adaptive Behavior Scales, Third Edition (Vineland-3) is a Comprehensive Form Adaptive Behavior Composite and Domain Standard Scores Description: The Vineland-3 Comprehensive Form assesses adaptive behavior, including communication, daily living skills, and socialization. Adaptive Behavior Composite and domain standard scores range from 20 to 140. Higher scores indicate stronger adaptive functioning relative to the age-based norm group

    Time frame: At baseline and at routine-care follow-up 1, 3, 6, 12, and 24 months after the participant's last session, when the measure is obtained.

  9. Routine fertility hormone profile results

    Results of hormonal tests ordered in routine care for participants with diminished or low ovarian reserve, secondary infertility, or amenorrhea. Record the test name, result, and date when available. The registry does not require additional laboratory testing.

    Time frame: At baseline and at routine-care follow-up 6 months after the participant's last session, when the measure is obtained.

  10. Menstrual status and menstrual mapping

    Menstrual status and cycle information recorded in routine care, including amenorrhea or changes in menstrual pattern when documented.

    Time frame: At baseline and at routine-care follow-up 1, 3, 6, 12, and 24 months after the participant's last session, when the measure is obtained.

  11. Routine pelvic ultrasound findings

    Pelvic ultrasound findings documented during routine fertility care. Record available findings; the registry does not require additional ultrasound examinations.

    Time frame: At baseline and at routine-care follow-up 6 months after the participant's last session, when the measure is obtained.

  12. Routine hormonal and laboratory results

    Hormonal profile and other laboratory results obtained during routine care for azoospermia. Record each test name, result, and date when available. The registry does not require additional tests.

    Time frame: At baseline and at routine-care follow-up 6 months after the participant's last session, when the measure is obtained.

  13. Routine ultrasound findings

    Ultrasound findings documented during routine care for azoospermia. Record available findings; the registry does not require additional imaging.

    Time frame: At baseline and at routine-care follow-up 6 months after the participant's last session, when the measure is obtained.

  14. Testicular sperm aspiration findings

    TESA findings, including whether sperm were identified, when the procedure is performed as part of routine care. The registry does not require TESA.

    Time frame: At baseline and at routine-care follow-up 6 months after the participant's last session, when the measure is obtained.

07

Study locations

1 site
  • Njinsky Medical Centre
    Lahore, Punjab Province 54000, Pakistan
08

References and documents

Publications

  • Zhankina R, Baghban N, Askarov M, Saipiyeva D, Ibragimov A, Kadirova B, Khoradmehr A, Nabipour I, Shirazi R, Zhanbyrbekuly U, Tamadon A. Mesenchymal stromal/stem cells and their exosomes for restoration of spermatogenesis in non-obstructive azoospermia: a systemic review. Stem Cell Res Ther. 2021 Apr 6;12(1):229. doi: 10.1186/s13287-021-02295-9. PubMed 33823925 ↗
  • Confalonieri F, La Rosa A, Ottonelli G, Barone G, Ferraro V, Di Maria A, Romano M, Randazzo A, Vallejo-Garcia JL, Vinciguerra P, Petrovski G. Retinitis Pigmentosa and Therapeutic Approaches: A Systematic Review. J Clin Med. 2024 Aug 9;13(16):4680. doi: 10.3390/jcm13164680. PubMed 39200821 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for Dec 2030, 48 months later.

Of 48 observational studies under Retinitis Pigmentosa, half reached primary completion within 76 months of starting (the median), counting those still running; a quarter within 28. This study's planned 48 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 5, 2026
First posted
Nov 17, 2026
StartEst.
Dec 1, 2026
Primary completionEst.
Dec 30, 2030
CompletionEst.
Dec 30, 2032
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07941544
Lead sponsor
Njinsky Medical Centre
Responsible party
Azra Mehmood (Associate Professor, Njinsky Medical Centre) — Principal investigator
First posted
Nov 17, 2026
Start date
Dec 1, 2026 (estimated)
Primary completion
Dec 30, 2030 (estimated)
Completion
Dec 30, 2032 (estimated)
Last update
Nov 17, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion